Nashville, Tennessee Clinical Trials

A listing of Nashville, Tennessee clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 64 clinical trials
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

vitamin b12 level
pemetrexed
stage iv non-small cell lung cancer
ros1
adjuvant therapy
Tennessee Oncology - Nashville (SCRI)
 (1.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +27 other locations
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Endocrine therapy is the initial treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancers. This study will evaluate the use of venetoclax in combination with capecitabine in adult participants with HR+, HER2-, metastatic breast cancer (MBC) who had disease progression following treatment …

endocrine therapy
HER2
cancer
metastatic breast cancer
hormone therapy
Vanderbilt University Med Ctr /ID# 213852
 (2.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +15 other locations
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

erbb1
her2/neu-negative breast cancer
epidermal growth factor receptor
her2- breast cancer
estrogen receptor
Tennessee Oncology
 (1.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +6 other locations
A Study of AK104 a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.

bevacizumab
squamous cell carcinoma
cervical carcinoma
cancer
major surgery
Sarah Cannon Research Institute
 (1.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +19 other locations
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

indirect bilirubin
cancer
metastatic malignant solid tumor
platelet count
absolute neutrophil count
Sarah Cannon Research Institute
 (1.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.

ovarian cancer
solid tumour
cancer
alopecia
non-small cell lung cancer
Sarah Cannon Research Institute (SCRI)
 (1.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +2 other locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

antiandrogen therapy
prostatic neoplasm
prostatic neoplasms, castration-resistant
combination therapy
taxane
Tennessee Oncology - Nashville
 (1.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +21 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

eliglustat
imiglucerase
gaucher disease
deficiency
Investigational Site Number 840049
 (0.3 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +208 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

gaa gene
myozyme
glycogen storage disease type ii
deficiency
replacement therapy
Investigational Site Number 840049
 (0.3 away) Contact site
  • 0 views
  • 22 Dec, 2020
  • +168 other locations
Fabry Disease Registry & Pregnancy Sub-registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary …

agalsidase beta
alpha-galactosidase
fabrazyme
fabry's disease
deficiency
Investigational Site Number 840049
 (0.3 away) Contact site
  • 0 views
  • 22 Dec, 2020
  • +125 other locations